Get started
Author

Elena Guerini‐Rocco

Observed names: E Guerini-Rocco, E. Guerini-Rocco, ELENA GUERINI-ROCCO, Elena Guerini Rocco, Elena Guerini Rocco2, Elena Guerini-Rocco
Observed institutions: Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Memorial Sloan Kettering Cancer Center, Humanitas University, University of Padua, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Chieti-Pescara, Ospedale San Paolo, Istituto Oncologico Veneto, Istituto Oncologico Romagnolo, Istituti di Ricovero e Cura a Carattere Scientifico, National Research Council, University of Turin, European Institute of Oncology, Institut Curie
ORCID: 0000-0003-2001-7582
Observed ORCID: 0000-0003-2001-7582
OpenAlex ID: A5017749409
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
2015 · Leticia De Mattos-Arruda, Regina Mayor, et al. · Nature Communications · 868
PDF
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk
2015 · Tari A. King, Melissa Pilewskie, et al. · Journal of Clinical Oncology · 208
PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
2020 · Nicola Fusco, Elham Sajjadi, et al. · Genes · 166
PDF
The Genomic Landscape of Male Breast Cancers
2016 · Salvatore Piscuoglio, Charlotte K.Y. Ng, et al. · Clinical Cancer Research · 151
PDF
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
2022 · Konstantinos Venetis, Edoardo Crimini, et al. · Frontiers in Molecular Biosciences · 146
PDF
E‐cadherin deregulation in breast cancer
2020 · Giovanni Corso, Joana Figueiredo, et al. · Journal of Cellular and Molecular Medicine · 129
PDF
Small cell carcinoma of the gynecologic tract: A multifaceted spectrum of lesions
2014 · Maria Atienza-Amores, Elena Guerini-Rocco, et al. · Gynecologic Oncology · 110
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors
2017 · Antonio Marchetti, Massimo Barberis, et al. · Journal of Thoracic Oncology · 103
PDF
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
2023 · Mariia Ivanova, Francesca Maria Porta, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 100
PDF
Dynamic Retention of Ero1α and Ero1β in the Endoplasmic Reticulum by Interactions with PDI and ERp44
2006 · Mieko Otsu, Gloria Bertoli, et al. · Antioxidants and Redox Signaling · 96
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis
2022 · Zheqi Li, Yang Wu, et al. · Cancer Research · 84
PDF
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer
2016 · Nicola Fusco, Felipe C Geyer, et al. · Modern Pathology · 82
PDF
HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions
2013 · Nicola Fusco, Elena Guerini Rocco, et al. · Modern Pathology · 80
PDF
The genetic landscape of breast carcinomas with neuroendocrine differentiation
2016 · Caterina Marchiò, Felipe C Geyer, et al. · The Journal of Pathology · 76
PDF
Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family
2016 · Felipe C Geyer, Samuel H Berman, et al. · Modern Pathology · 74
PDF
Understanding EGFR heterogeneity in lung cancer
2020 · Antonio Passaro, Umberto Malapelle, et al. · ESMO Open · 73
PDF
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
2017 · Antonio Passaro, Elena Guerini-Rocco, et al. · Pharmacological Research · 72
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study
2015 · Elena Guerini‐Rocco, Zsolt Hodi, et al. · The Journal of Pathology · 72
PDF
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
2023 · Konstantinos Venetis, Francesco Pepe, et al. · Cancer Treatment Reviews · 67
Microglandular adenosis associated with triple‐negative breast cancer is a neoplastic lesion of triple‐negative phenotype harbouring TP53 somatic mutations
2016 · Elena Guerini‐Rocco, Salvatore Piscuoglio, et al. · The Journal of Pathology · 65
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
2022 · Fabio Conforti, Paolo Andrea Zucali, et al. · The Lancet Oncology · 64
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
2019 · Fabio Pagni, Elena Guerini-Rocco, et al. · International Journal of Molecular Sciences · 62
PDF
Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review
2020 · Giovanni Corso, Giacomo Montagna, et al. · Cancers · 59
PDF
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
2020 · Caterina Fumagalli, Alberto Ranghiero, et al. · Breast Cancer Research · 54
PDF
Are acinic cell carcinomas of the breast and salivary glands distinct diseases?
2015 · Salvatore Piscuoglio, Zsolt Hodi, et al. · Histopathology · 54
Works count: 266
Citation count: 5,444
H-index: 38
I10-index: 109
Year
Topic
Type